NCT03332329 (NPGV) is a Phase 4 clinical trial of Entecavir in Chronic Hepatitis b, sponsored by Qin Ning.

Who is sponsoring NCT03332329?

NCT03332329 is sponsored by Qin Ning.

What drugs are being tested in NCT03332329?

Interventions in NCT03332329: Entecavir, Granulocyte Macrophage Colony Stimulating Factor, Y peginterferon alfa-2b, HBV vaccine.

What condition does NCT03332329 study?

NCT03332329 studies Chronic Hepatitis b.

Is NCT03332329 still recruiting?

NCT03332329 is currently status unknown. Last updated 6 November 2017.

Last reviewed 2017-11-06 · How we verify

NCT03332329: NPGV

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sequential/Combination Therapy in Nucleoside or Nucleotide Analogue (NA)-Suppressed Chronic Hepatitis B Patients

Status unknown Phase 4 Last updated 6 November 2017

What this trial tests

Phase 4 trial testing Entecavir in Chronic Hepatitis b in 15 participants. Status unknown.

Timeline

1 December 2015

Primary endpoint
31 December 2018

31 December 2019

Quick facts

Lead sponsor	Qin Ning
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	1 December 2015
Primary completion	31 December 2018
Estimated completion	31 December 2019

Drugs / interventions tested

Entecavir (ENTECAVIR) — full drug profile →
Granulocyte Macrophage Colony Stimulating Factor — full drug profile →
Y peginterferon alfa-2b — full drug profile →
HBV vaccine — full drug profile →

Conditions studied

Chronic Hepatitis b — all drugs for Chronic Hepatitis b →

Sponsor

Qin Ning — full company profile →

Who can join

Adults 18 to 65, any sex, with Chronic Hepatitis b. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the prospective study is to determine whether combination/ sequential therapy with Entecavir, Peginterferon alfa-2b and immunomodulators Granulocyte Macrophage Colony Stimulating Factor (GMCSF)+vaccine could induce HBsAg loss in chronic hepatitis B patients with maintained Hepatitis B Virus (HBV) DNA suppression on long-term nucleoside or nucleotide analogue (NA).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Entecavir

Trials testing the same drug.

NCT07345611 — Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Active Chronic Hepatitis B · Phase 4 · not yet recruiting
NCT07345624 — Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Tolerant Chronic Hepatitis B · Phase 4 · not yet recruiting
NCT07295873 — Drug-Drug Interaction Study Between Hydronidone and Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide, and · Phase 1 · not yet recruiting
NCT06966232 — Prophylactic or Preemptive Entecavir in Patients With Gastrointestinal Cancer Who Are Inactive Hepatitis B Carriers · Phase 3 · recruiting
NCT05423834 — Chronic Kidney Disease Progression in Chronic Hepatitis B Patients on Tenofovir Alafenamide (TAF) Versus Entecavir · active not recruiting

Other recruiting trials for Chronic Hepatitis b

Currently open trials in the same condition.

NCT07090759 — To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatitis B (CHB) · Phase 3 · recruiting
NCT06989788 — A Study to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for Chronic Hepatitis B Virus Infection, · Phase 1 · active not recruiting
NCT06885710 — HBV-Specific TCR-T Cell Therapy Combined With Nucleos(t)Ide Analogues in Chronic Hepatitis B Patients · Phase 1 · recruiting
NCT06671093 — Phase 1b, Open-label Study of Tune-401 to Assess Safety, PK and PD in Adults With Chronic Hepatitis B · Phase 1 · recruiting
NCT06638320 — Hepatitis Delta Virus Infection: Cross-sectional Study in Patients With Chronic Hepatitis B Virus Infection · active not recruiting

Other Qin Ning trials

Trials by the same sponsor.

NCT06365073 — A Case-control Study on the Clinical Characteristics of 28-day and 90-day Death From Severe Anthrax · recruiting
NCT05780190 — Clinical Observation of CABA System in the Treatment of End-stage Liver Disease With Inflammation · Phase 4 · unknown
NCT06437067 — Study on Prognosis of Acute-on-chronic Liver Failure Complicated by Bacterial or Fungal Infection · recruiting
NCT05604859 — Evaluate the Efficacy and Safety of Various Treatment Schemes for Severe Fever With Thrombocytopenia Syndrome(SFTS) · Phase 4 · unknown
NCT06007326 — A Multicentre, Retrospective Study of Clinical Characteristics and Long-term Outcomes of Patients With Brucellosis · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03332329 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Qin Ning
Last refreshed: 6 November 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03332329.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing